- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03264976
Role of the Serum Exosomal miRNA in Diabetic Retinopathy (DR)
Prognostic Role of Serum Exosomal miRNA and Its Function in Pathogenesis of Diabetic Retinopathy (DR)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients will be chosen according to the inclusion and exclusion standard and written informed consent will be obtained from all participants.
Exit criteria: During the research, for his / her own consideration or at the request of the investigator the patient may withdraw from the trial at any time. For each subject who withdrew from the trial, the investigator must detail the subject's exit date, the reason, and other information in case report form(CRF).
Description
Inclusion Criteria:
- Type II diabetics,
- Age > 18 years old,
- Have not accepted anti-VEGF therapy,
- Without turbid ocular media or corestenoma that interfere with ophthalmic fundus examination (patients with PDR are excluded).
Exclusion Criteria:
-Patients with any following eye disease in studied eye:
- active infections (i.e., blepharitis, keratitis, scleritis, conjunctivitis, etc.),
- fundus oculi diseases other than DR (i.e., retinal vein occlusion, choroidal neovascularization, retinal detachment, macular hole, vitreous traction in macular region, epiretinal membrane, etc.) ,
uncontrollable glaucoma (intraocular pressure is no less than 25mmHg after anti-glaucoma agents) or after filtering surgery for glaucoma;
-Patients who have accepted any following treatment in studied eyes:
- intraocular injection of corticosteroids (i.e., Triamcinolone) within 3 months, or peribulbar injection of corticosteroids within 1 months,
- vitrectomy surgery,
- anti-VEGF therapy for eyes or other parts of the body (i.e., ranibizumab, bevacizumab, conbercept, aflibercept, pegaptanib sodium, etc),
- any intraocular surgery within 3 months (i.e., cataract surgery, YAG laser capsulectomy, etc),
ocular surgery related with macular region;
-Patients with any following systemic diseases:
- failed blood sugar control within 3 months (Changing treatment from oral antidiabetic therapy into insulin treatment, or start using insulin pump, or doubling the number of injections),
- damaged renal function (Crea is found to be 2 times higher than the upper limit in central laboratory) or abnormal liver function (ALT, AST are found to be 2 times higher than the upper limit in center of the laboratory),
- failed blood pressure control within 3 months (systolic blood pressure is no less than 140 mmHg or diastolic blood pressure is no less than 90 mmHg after hypotensor treatment),
- systemic infection that requires oral, intramuscular or intravenous administration,
- stroke, transient ischemic attack, myocardial infarction or acute congestive heart failure within 6months,
- coagulation dysfunction (thrombin time ≥ normal upper limit of 3 seconds, activation of partial thromboplastin time ≥ normal upper limit of 10 seconds),
- using drugs that may be toxic to the lens, retina or optic nerve during this research (i.e., deferoxamine, chloroquine, hydrogenated chloroquine (chloroquinol), tamoxifen, phenothiazine, or ethambutol, etc.),
diagnosed systemic immune diseases (i.e., mandatory spondylitis, systemic lupus erythematosus, etc.) or any uncontrollable clinical diseases (such as AIDS, malignancy, active hepatitis, severe mental, neurological, cardiovascular, respiratory and other systems diseases, etc.);
-Others:
- pregnant and lactating women,
- those who participated in any drug clinical trials (not including vitamins and minerals) within 3 months,
- those researchers believe that need to be excluded.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group 1
Patients without DR.
Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.
These information and examinations will be collected at regular intervals: every 12 months until 5 years.
|
Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP);Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
|
Group 2
Patients with mild non-proliferative DR (NPDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016. Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years. |
Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP);Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
|
Group 3
Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016. Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years. |
Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP);Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
|
Group 4
Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016. Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years. |
Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP);Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
|
Group 5
Proliferative DR (PDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016. Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years. |
Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP);Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
exosomal miRNAs in serum samples
Time Frame: samples will be collected every 12 months later until 5 years
|
In discovery set, miRNA sequencing of serum exosomes will be performed for each sample.
Data will be analyzed using statistical methods.
Potential miRNAs that show group-differentiation will be selected in combination with information and test results.Based on these selected miRNAs, the same assays will be repeated on all validation set samples to screen out significant miRNA.
|
samples will be collected every 12 months later until 5 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-KE-194
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Retinopathy
-
Retina Institute of HawaiiUnknownDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Severe Nonproliferative Diabetic Retinopathy | Mild Nonproliferative Diabetic Retinopathy | Moderate Nonproliferative Diabetic RetinopathyUnited States
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Asociación para Evitar la Ceguera en MéxicoCompletedProliferative Diabetic Retinopathy | Severe Nonproliferative | Active Photocoagulated Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownNon Proliferative Diabetic Retinopathy. | Proliferative Diabetic Retinopathy.Mexico
-
Valo Health, Inc.RecruitingProliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
-
AEYE Health IncA. Stein Regulatory Affairs Consulting Ltd.RecruitingDiabetic Mellitus | Diabetic Retinopathy, DRUnited States
-
Ocuphire Pharma, Inc.CompletedDiabetic Retinopathy | Diabetic Macular Edema | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferative Diabetic RetinopathyUnited States
-
King Khaled Eye Specialist HospitalCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathySaudi Arabia
-
Retina Macula InstituteAllerganCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
Clinical Trials on hematological examination, ophthalmic examination
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityThe First Affiliated Hospital of Guangzhou Medical UniversityNot yet recruitingArtificial Intelligence | Pulmonary Diseases | Ophthalmological Diagnostic TechniquesChina
-
Sakarya UniversityCompletedStrabismus | Amblyopia | Astigmatism of Both EyesTurkey
-
Third Affiliated Hospital, Sun Yat-Sen UniversityUnknownDiabetes Mellitus | Diabetic Retinopathy | Nerve InjuryChina
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityCompleted
-
Vanderbilt University Medical CenterAllerganCompletedNervous System Diseases | Neurologic Manifestations | Muscular Diseases | Neuromuscular Manifestations | Muscle Hypertonia | Spasticity, Muscle | Muscle Spasticity | Musculoskeletal Disease | Signs and SymptomsUnited States
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Adiyaman University Research HospitalNot yet recruitingPostdural Puncture HeadacheTurkey
-
Brugmann University HospitalCompletedFetal MacrosomiaBelgium
-
University Hospital, Basel, SwitzerlandDePuy SynthesRecruitingArthroscopic Rotator Cuff Repair (ARCR)Switzerland